CA3158292A1 - Methods of treating pulmonary arterial hypertension - Google Patents

Methods of treating pulmonary arterial hypertension Download PDF

Info

Publication number
CA3158292A1
CA3158292A1 CA3158292A CA3158292A CA3158292A1 CA 3158292 A1 CA3158292 A1 CA 3158292A1 CA 3158292 A CA3158292 A CA 3158292A CA 3158292 A CA3158292 A CA 3158292A CA 3158292 A1 CA3158292 A1 CA 3158292A1
Authority
CA
Canada
Prior art keywords
combination therapy
initial
patient
pah
triple combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3158292A
Other languages
English (en)
French (fr)
Inventor
Alessandro MARESTA
Loic Perchenet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Maresta Alessandro
Perchenet Loic
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73726769&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3158292(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Maresta Alessandro, Perchenet Loic, Actelion Pharmaceuticals Ltd filed Critical Maresta Alessandro
Publication of CA3158292A1 publication Critical patent/CA3158292A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3158292A 2019-11-29 2020-11-27 Methods of treating pulmonary arterial hypertension Pending CA3158292A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962941910P 2019-11-29 2019-11-29
US62/941,910 2019-11-29
US202063023452P 2020-05-12 2020-05-12
US63/023,452 2020-05-12
US202063076149P 2020-09-09 2020-09-09
US63/076,149 2020-09-09
PCT/EP2020/083593 WO2021105331A1 (en) 2019-11-29 2020-11-27 Methods of treating pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
CA3158292A1 true CA3158292A1 (en) 2021-06-03

Family

ID=73726769

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3158292A Pending CA3158292A1 (en) 2019-11-29 2020-11-27 Methods of treating pulmonary arterial hypertension

Country Status (18)

Country Link
US (1) US12485119B2 (https=)
EP (1) EP4065119B1 (https=)
JP (3) JP7721520B2 (https=)
KR (1) KR20220106974A (https=)
CN (1) CN114728002A (https=)
AU (1) AU2020392424A1 (https=)
BR (1) BR112022010311A2 (https=)
CA (1) CA3158292A1 (https=)
CR (1) CR20220305A (https=)
EC (1) ECSP22051163A (https=)
ES (1) ES2994089T3 (https=)
IL (1) IL293271A (https=)
JO (1) JOP20220127A1 (https=)
MX (1) MX2022006403A (https=)
PE (1) PE20221320A1 (https=)
PH (1) PH12022551294A1 (https=)
TW (1) TW202133851A (https=)
WO (1) WO2021105331A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024099953A1 (en) * 2022-11-07 2024-05-16 Actelion Pharmaceuticals Ltd Combination of macitentan and tadalafil for the treatment of pulmonary arterial hypertension
KR102663470B1 (ko) * 2023-03-16 2024-05-10 주식회사 케어사이드 폐성 고혈압에 의한 심장 질환 예방 및 심장 치료용 조성물 및 이를 포함하는 기능성 제제

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002227984B8 (en) 2000-12-18 2007-01-04 Actelion Pharmaceuticals Ltd. Novel sulfamides and their use as endothelin receptor antagonists
TWI316055B (https=) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
JP5764061B2 (ja) 2008-08-13 2015-08-12 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ マシテンタン含有治療用組成物
LT2447254T (lt) 2009-06-26 2018-01-10 Nippon Shinyaku Co., Ltd. Kristalai
WO2011024874A1 (ja) 2009-08-26 2011-03-03 日本新薬株式会社 塩基付加塩
MX346730B (es) 2010-10-15 2017-03-30 Gilead Sciences Inc Composiciones y metodos para el tratamiento de la hipertension pulmonar.
EP3136101B1 (en) 2014-04-22 2019-12-25 Tohoku University Method of testing for pulmonary hypertension
CN107427698A (zh) 2015-01-13 2017-12-01 维瓦斯公司 肺高血压的组合疗法
CA3041679A1 (en) 2016-10-27 2018-05-03 Lawrence S. ZISMAN Combination therapy for treating pulmonary hypertension
PT3897646T (pt) * 2018-12-21 2024-07-08 Actelion Pharmaceuticals Ltd Macitentano para tratamento de hipertensão arterial pulmonar

Also Published As

Publication number Publication date
CR20220305A (es) 2022-07-28
BR112022010311A2 (pt) 2022-08-16
PH12022551294A1 (en) 2023-11-20
KR20220106974A (ko) 2022-08-01
PE20221320A1 (es) 2022-09-08
US20230032813A1 (en) 2023-02-02
JP7721520B2 (ja) 2025-08-12
JP7620758B2 (ja) 2025-01-23
JP2023504115A (ja) 2023-02-01
EP4065119B1 (en) 2024-09-04
AU2020392424A1 (en) 2022-06-02
JOP20220127A1 (ar) 2023-01-30
ES2994089T3 (en) 2025-01-17
MX2022006403A (es) 2022-08-25
EP4065119A1 (en) 2022-10-05
WO2021105331A1 (en) 2021-06-03
JP2024153734A (ja) 2024-10-29
CN114728002A (zh) 2022-07-08
TW202133851A (zh) 2021-09-16
IL293271A (en) 2022-07-01
ECSP22051163A (es) 2022-07-29
JP2025172745A (ja) 2025-11-26
US12485119B2 (en) 2025-12-02

Similar Documents

Publication Publication Date Title
AU2024203872A1 (en) Treatment of HCM with pyrimidinedione compounds
US9532984B2 (en) Therapeutic combination for cancer treatment
JP7620758B2 (ja) 肺動脈性肺高血圧症の治療方法
US20220323437A1 (en) Methods for treating pulmonary arterial hypertension
AU2023201638A1 (en) Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders
KR20080081358A (ko) Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법
US20220257595A1 (en) Macitentan for use in treating portopulmonary hypertension
US20250205235A1 (en) Dose regimen for vericiguat
AU2018283781B2 (en) Method for reducing or preventing cardiovascular events in patients with type II diabetes mellitus
US20240366596A1 (en) Treatment of hfpef in post-menopausal women with an sgc stimulator
US20240299384A1 (en) Methods for treating pulmonary hypertension in patients with left ventricular assist device implantation
WO2022238375A1 (en) Methods of treating pulmonary hypertension
WO2024099953A1 (en) Combination of macitentan and tadalafil for the treatment of pulmonary arterial hypertension
CA3269490A1 (en) Methods of treating estrogen receptor-mediated disorders
EP4598520A1 (en) Methods of treating estrogen receptor-mediated disorders

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260109

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260202